Probiotic Supplementation and Pancreatic β-Cell Function in Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

December 15, 2021

Conditions
Type2 DiabetesObesityInsulin ResistanceObesity, Abdominal
Interventions
DIETARY_SUPPLEMENT

Probiotic

The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa

DIETARY_SUPPLEMENT

Placebo

Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day

Trial Locations (4)

01601

Bogomolets National Medical University, Kyiv

Kyiv City Clinical Endocrinology Center, Kyiv

Taras Shevchenko National University of Kyiv, Kyiv

Unknown

Danylo Halytsky Lviv National Medical University, Lviv

All Listed Sponsors
collaborator

Taras Shevchenko National University of Kyiv

OTHER

collaborator

Danylo Halytsky Lviv National Medical University

OTHER

collaborator

Kyiv City Clinical Endocrinology Center

OTHER

lead

Bogomolets National Medical University

OTHER

NCT05765292 - Probiotic Supplementation and Pancreatic β-Cell Function in Type 2 Diabetes | Biotech Hunter | Biotech Hunter